{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T19:43:14Z","timestamp":1767901394113,"version":"3.49.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ad.2023.09.001","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T01:37:45Z","timestamp":1694223465000},"page":"T865-T883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["[Translated article] Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study"],"prefix":"10.1016","volume":"114","author":[{"given":"L.","family":"Salgado-Boquete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Arias-Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Belinch\u00f3n-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"de la Cuadra-Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Gilaberte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Notario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rivera-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.ad.2023.09.001_bib0425","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"Pt 1","key":"10.1016\/j.ad.2023.09.001_bib0430","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0435","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40257-013-0032-x","article-title":"Burden of disease: psoriasis and psoriatic arthritis","volume":"14","author":"Boehncke","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0440","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0445","first-page":"1","article-title":"Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study","volume":"5","author":"Narayanan","year":"2015","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.ad.2023.09.001_bib0450","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ad.2020.11.017","article-title":"Burden of psoriasis in Catalonia: epidemiology, associated comorbidities health care utilization, and sick leave","volume":"112","author":"Puig","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0455","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ad.2021.10.006","article-title":"Dermatology care in Spanish public hospitals: a mapping study of health care resources and medical and surgical activity in dermatology departments in 2019","volume":"113","author":"Cuenca-Barrales","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0460","unstructured":"Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda (AEDV). Libro Blanco de la Dermatolog\u00eda, 2008. Available from: https:\/\/aedv.es\/wp-content\/uploads\/2015\/04\/LibroBlancoDerma.pdf [cited 2022 July 12]."},{"key":"10.1016\/j.ad.2023.09.001_bib0465","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ueg2.12105","article-title":"Inflammatory bowel disease integral care units: evaluation of a nationwide quality certification programme. The GETECCU experience","volume":"9","author":"Barreiro-de Acosta","year":"2021","journal-title":"Unit Eur Gastroenterol J"},{"key":"10.1016\/j.ad.2023.09.001_bib0470","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/2396987318778971","article-title":"European Stroke Organisation certification of stroke units and stroke centres","volume":"3","author":"Waje-Andreassen","year":"2018","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.ad.2023.09.001_bib0475","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00296-020-04632-2","article-title":"Evaluating standards of care in psoriatic arthritis of the QUANTUM project (qualitative initiative to improve outcomes): results of an accreditation project in Spain","volume":"40","author":"Garc\u00eda","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ad.2023.09.001_bib0480","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/intqhc\/mzg081","article-title":"Defining and classifying clinical indicators for quality improvement","volume":"15","author":"Mainz","year":"2003","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.ad.2023.09.001_bib0485","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1751-2824.2012.01584.x","article-title":"Quality indicators: a tool for quality monitoring and improvement: quality indicators","volume":"7","author":"Vuk","year":"2012","journal-title":"ISBT Sci Ser"},{"key":"10.1016\/j.ad.2023.09.001_bib0490","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00403-014-1534-y","article-title":"Treatment goals in psoriasis routine care","volume":"307","author":"Radtke","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.ad.2023.09.001_bib0495","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ad.2019.06.007","article-title":"Indicadores de calidad en la atenci\u00f3n dermatol\u00f3gica a pacientes con dermatitis at\u00f3pica. Documento de consenso de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda","volume":"111","author":"Poveda-Montoyo","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0500","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00296-018-3986-4","article-title":"Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain","volume":"38","author":"Gratac\u00f3s","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ad.2023.09.001_bib0505","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.reuma.2016.03.005","article-title":"Modelos de atenci\u00f3n multidisciplinar en pacientes con artritis psori\u00e1sica en Espa\u00f1a","volume":"13","author":"Queiro","year":"2017","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.ad.2023.09.001_bib0510","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.reuma.2018.06.011","article-title":"Norma de calidad para el manejo del paciente con artritis psori\u00e1sica: proyecto QUANTUM","volume":"16","author":"Sanz Sanz","year":"2020","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.ad.2023.09.001_bib0515","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ad.2018.06.004","article-title":"Evaluation of structure indicators for assessing skin cancer quality of care in dermatology departments","volume":"109","author":"Kueder-Pajares","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0520","unstructured":"Alonso Carri\u00f3n L, Arance Fern\u00e1ndez A, Aristu Mendioroz JJ, Berrocal Jaime A, Botella Estrada R, Cajaraville Ordo\u00f1ana, et al. La calidad en la atenci\u00f3n a pacientes con melanoma cut\u00e1neo. Proceso de atenci\u00f3n al paciente con melanoma cut\u00e1neo. Available from: https:\/\/calidadasistencial.es\/wp-content\/uploads\/2015\/02\/350-melanoma-cutaneo.pdf [cited 2022 July 12]."},{"key":"10.1016\/j.ad.2023.09.001_bib0525","first-page":"139","article-title":"Quality assurance for care of melanoma patients based on guideline-derived quality indicators and certification: quality management melanoma","volume":"12","author":"Follmann","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2023.09.001_bib0530","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3899\/jrheum.190120","article-title":"Best-practice indicators in psoriatic disease care","volume":"95","author":"Helliwell","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0535","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.ad.2023.09.001_bib0540","first-page":"655","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.ad.2023.09.001_bib0545","series-title":"The Delphi survey: method techniques and applications","author":"Linstone","year":"1975"},{"key":"10.1016\/j.ad.2023.09.001_bib0550","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0048-7120(01)73220-3","article-title":"M\u00e9todos de consenso. Uso adecuado de la evidencia en la toma de decisiones. \u00abM\u00e9todo RAND\/UCLA\u00bb","volume":"35","author":"Mart\u00ednez-Sahuquillo Amuedo","year":"2001","journal-title":"Rehabilitacion"},{"key":"10.1016\/j.ad.2023.09.001_bib0555","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ad.2012.10.019","article-title":"Expert report on psoriasis: Spanish dermatologists\u2019 opinions on the use of biologic agents to manage moderate to severe psoriasis in adults","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0560","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11845-016-1424-8","article-title":"An analysis of inpatient dermatologic consultations at University Hospital Limerick: inadequate infrastructure leads to acute skin failure","volume":"186","author":"Alani","year":"2017","journal-title":"Ir J Med Sci"},{"key":"10.1016\/j.ad.2023.09.001_bib0565","first-page":"14","article-title":"Providing guidance for patients with moderate-to-severe psoriasis who are candidates for biologic therapy: role of the nurse practitioner and physician assistant","volume":"8","author":"Aldredge","year":"2016","journal-title":"J Dermatol Nurses Assoc"},{"key":"10.1016\/j.ad.2023.09.001_bib0570","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaad.2015.11.045","article-title":"Translating psoriasis guidelines into practice: important gaps revealed","volume":"74","author":"Bhushan","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0575","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","article-title":"Redefining the therapeutic objective in psoriatic patients candidates for biological therapy","volume":"29","author":"Carretero","year":"2018","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2023.09.001_bib0580","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.13512","article-title":"Biosimilars in psoriasis: clinical practice and regulatory perspectives in Latin America","volume":"44","author":"de la Cruz","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0585","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1080\/09546634.2020.1826394","article-title":"Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review","volume":"33","author":"Ghamrawi","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2023.09.001_bib0590","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0595","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaad.2014.11.010","article-title":"Impact of a Performance Improvement CME activity on the care and treatment of patients with psoriasis","volume":"72","author":"Gist","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0600","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2133.2006.07354.x","article-title":"The impact of psoriasis guidelines on appropriateness of referral from primary to secondary care: a randomized controlled trial: psoriasis guidelines and referral","volume":"155","author":"Griffiths","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0605","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1203475420908250","article-title":"Optimizing communication about topical corticosteroids: a quality improvement study","volume":"24","author":"Johnson Girard","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ad.2023.09.001_bib0610","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12788\/cutis.0026","article-title":"Translating the 2019 AAD-NPF guidelines of care for the management of psoriasis with phototherapy","volume":"106","author":"Kearns","year":"2020","journal-title":"Cutis"},{"issue":"S1","key":"10.1016\/j.ad.2023.09.001_bib0615","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ijd.14471","article-title":"Latin American clinical practice guidelines on the systemic treatment of psoriasis SOLAPSO \u2013 Sociedad Latinoamericana de Psoriasis (Latin American Psoriasis Society)","volume":"58","author":"Kogan","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0620","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2340\/00015555-1809","article-title":"Implementing best practice in psoriasis: a Nordic expert group consensus","volume":"94","author":"Kragballe","year":"2014","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0625","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.reuma.2014.01.004","article-title":"Experiencia de 4 a\u00f1os de funcionamiento de una unidad multidisciplinar de psoriasis y artritis psori\u00e1sica","volume":"10","author":"Luelmo","year":"2014","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.ad.2023.09.001_bib0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04033.x","article-title":"Strategies for improving the quality of care in psoriasis with the use of treatment goals \u2013 a report on an implementation meeting: treatment goals to improve quality of care in psoriasis","volume":"25","author":"Mrowietz","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0635","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2753.2008.00971.x","article-title":"Translating psoriasis treatment guidelines into clinical practice \u2013 the need for educational interventions and strategies for broad dissemination: implementation of psoriasis guidelines","volume":"14","author":"Nast","year":"2008","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.ad.2023.09.001_bib0640","first-page":"2","article-title":"Practical use of biologic therapy in dermatology: some considerations and checklists","volume":"18","author":"Ortleb","year":"2012","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.ad.2023.09.001_bib0645","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0733-8635(03)00128-1","article-title":"Practical considerations in future psoriasis therapies","volume":"22","author":"Riddle","year":"2004","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ad.2023.09.001_bib0650","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/09546634.2018.1428723","article-title":"Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review","volume":"29","author":"Shah","year":"2018","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.ad.2023.09.001_bib0655","first-page":"23","article-title":"Preparing patients for biologic medications for dermatologic and rheumatic diseases","volume":"31","author":"Smith","year":"2018","journal-title":"J Am Acad Physician Assist"},{"key":"10.1016\/j.ad.2023.09.001_bib0660","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0001-7310(09)70821-X","article-title":"Documento de consenso sobre la evaluaci\u00f3n y el tratamiento de la psoriasis moderada\/grave del Grupo Espa\u00f1ol de Psoriasis de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda","volume":"100","author":"Puig","year":"2009","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0665","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ad.2018.10.007","article-title":"Documento de consenso sobre las necesidades psicol\u00f3gicas de los pacientes con enfermedades inflamatorias cr\u00f3nicas dermatol\u00f3gicas","volume":"110","author":"Ribera","year":"2019","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0670","unstructured":"Ruiz-Villaverde R, Gal\u00e1n Guti\u00e9rrez M, Rodr\u00edguez Fern\u00e1ndez-Freire L. Gu\u00eda Para Pacientes Con Psoriasis, 2021. Available from: https:\/\/psoriasisenred.org\/guia-para-pacientes-con-psoriasis-de-la-academia-espanola-de-dermatologia\/ [cited 2022 July 12]."},{"key":"10.1016\/j.ad.2023.09.001_bib0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.13542","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"30","author":"Daud\u00e9n","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0680","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0685","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0690","unstructured":"Grupo de Psoriasis (GPs) de la Academia Espa\u00f1ola de Dermatolog\u00eda y Venereolog\u00eda (AEDV). Proceso Asistencial Psoriasis, 2021. Available from: https:\/\/aedv.es\/wp-content\/uploads\/2016\/07\/Proceso-asistencial.pdf [cited 2022 July 12]."},{"key":"10.1016\/j.ad.2023.09.001_bib0695","series-title":"Por una atenci\u00f3n sanitaria m\u00e1s humanizada de las personas con psoriasis","author":"Fern\u00e1ndez-Lasquetty Blanc","year":"2019"},{"key":"10.1016\/j.ad.2023.09.001_bib0700","unstructured":"Calvet X, Chaparro M, Dom\u00e8nech E, Esteve M, Nos P, Pan\u00e9s J, et al. Normalizaci\u00f3n de los indicadores de calidad para unidades de atenci\u00f3n integral a pacientes con enfermedad inflamatoria intestinal, 2016. Available from: https:\/\/geteccu.org\/contenidos\/up\/2016\/12\/Documento-1.pdf [cited 2022 July 12]."},{"key":"10.1016\/j.ad.2023.09.001_bib0705","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ad.2020.06.004","article-title":"El papel del dermat\u00f3logo en el diagn\u00f3stico precoz de la artritis psori\u00e1sica: recomendaciones de un grupo de expertos","volume":"111","author":"Belinch\u00f3n","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0710","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ad.2020.05.004","article-title":"Managing psoriasis consultations during the COVID-19 pandemic: recommendations from the psoriasis group of the Spanish Academy of Dermatology and Venereology (AEDV)","volume":"111","author":"Belinch\u00f3n","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0715","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ad.2010.11.002","article-title":"Documento de consenso de fototerapia en psoriasis del Grupo Espa\u00f1ol de Psoriasis: ultravioleta B de banda estrecha (UVBBE), l\u00e1ser y fuentes monocrom\u00e1ticas de exc\u00edmeros y terapia fotodin\u00e1mica","volume":"102","author":"Carrascosa","year":"2011","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0720","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ad.2016.04.017","article-title":"Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales (II)","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0725","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ad.2015.10.005","article-title":"Metotrexato en psoriasis moderada-grave: revisi\u00f3n de la literatura y recomendaciones de experto","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0730","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ad.2010.04.002","article-title":"Metotrexato: gu\u00eda de uso en psoriasis","volume":"101","author":"Carretero","year":"2010","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0735","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0001-7310(07)70040-6","article-title":"Documento de consenso sobre la modalidad terap\u00e9utica del ba\u00f1o-PUVA","volume":"98","author":"Rodr\u00edguez-Granados","year":"2007","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0740","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3111\/13696998.2011.604369","article-title":"Pain, health related quality of life and healthcare resource utilization in Spain","volume":"14","author":"Langley","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.ad.2023.09.001_bib0745","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1610-0387.2008.06807.x","article-title":"Quality of psoriasis care in Germany \u2013 results of the national study PsoHealth 2007","volume":"6","author":"Augustin","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ad.2023.09.001_bib0750","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2215\/CJN.02590316","article-title":"Anxiety in patients treated with hemodialysis","volume":"11","author":"Cohen","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ad.2023.09.001_bib0755","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0760","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjd.20428","article-title":"Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines","volume":"185","author":"Haw","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0765","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/jid.2010.164","article-title":"Critical appraisal of quality of clinical practice guidelines for treatment of psoriasis vulgaris, 2006\u20132009","volume":"130","author":"Tan","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2023.09.001_bib0770","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1468-3083.2009.03166.x","article-title":"A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: \u2018AGREE-ing\u2019 on a common base for European evidence-based psoriasis treatment guidelines","volume":"23","author":"Nast","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0775","doi-asserted-by":"crossref","first-page":"adv00337","DOI":"10.2340\/00015555-3614","article-title":"Towards more shared decision making in dermatology: development of evidence-based decision cards for psoriasis and atopic eczema treatments","volume":"100","author":"Vermeulen","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0780","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12875-016-0544-6","article-title":"Severity and management of psoriasis within primary care","volume":"17","author":"Wade","year":"2016","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.ad.2023.09.001_bib0785","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ad.2009.12.007","article-title":"Comentarios a las directrices europeas y brit\u00e1nicas sobre el tratamiento de la psoriasis","volume":"101","author":"Puig","year":"2010","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0790","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0795","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/jdv.16684","article-title":"Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1)","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0800","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/jdv.16683","article-title":"Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2)","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0805","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris \u2013 Update 2015 \u2013 Short version \u2013 EDF in cooperation with EADV and IPC","volume":"29","author":"Nast","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0810","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-Guideline on the systemic treatment of psoriasis vulgaris \u2013 update Apremilast and Secukinumab \u2013 EDF in cooperation with EADV and IPC","volume":"31","author":"Nast","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-Guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2023.09.001_bib0820","unstructured":"International Federation of Psoriasis Associations (IFPA), International League of Dermatological Societies (ILDS), International Psoriasis Council (IPC). Global Psoriasis Atlas. Annual Report. Year 3: April 2019\u2013March 2020. Available from: https:\/\/www.psoriasiscouncil.org\/wp-content\/uploads\/2022\/06\/gpa_2020_annual_report_year_3.pdf [cited 2022 July 12]."},{"key":"10.1016\/j.ad.2023.09.001_bib0825","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ad.2020.10.002","article-title":"Consenso sobre las actuaciones a seguir durante la edad f\u00e9rtil, el embarazo, el posparto y la lactancia en pacientes con psoriasis","volume":"112","author":"Belinch\u00f3n","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2023.09.001_bib0830","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/14712598.2020.1798924","article-title":"Biosimilars in psoriasis: what should your positioning be(","volume":"21","author":"Ruiz-Villaverde","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ad.2023.09.001_bib0835","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/life11070627","article-title":"A new classification of the severity of psoriasis: what's moderate psoriasis","volume":"11","author":"Salgado-Boquete","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.ad.2023.09.001_bib0840","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ad.2014.02.015","article-title":"Directrices del grupo espa\u00f1ol de psoriasis (GEP) basadas en la evidencia para el uso de medicamentos biol\u00f3gicos en pacientes con psoriasis en localizaciones de dif\u00edcil tratamiento (u\u00f1as, cuero cabelludo, palmas y plantas)","volume":"105","author":"S\u00e1nchez-Rega\u00f1a","year":"2014","journal-title":"Actas Dermosifiliogr"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023006932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731023006932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:32:17Z","timestamp":1762075937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731023006932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0001731023006932"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2023.09.001","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2023.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEDV.","name":"copyright","label":"Copyright"}]}}